Life Science Dealmaking Trends 2025
In this series of videos, International Chair of Life Sciences Cheryl Reicin provides valuable insights on a number of trends she is seeing in Big Pharma dealmaking and M&A. She discusses 2025 deal trends, M&A drivers, patent cliff impacts, and the hottest emerging sectors.
Drivers of Big Pharma M&A
Big Pharma Patent Cliff Impacts to M&A
What are the Hottest Sectors in the Life Science Industry?
Central Nervous System (CNS) Investment Opportunities
How Do You See Big Pharmas in AI?
Author
Cheryl V. Reicin
Partner / International Chair, Life Sciences
Cheryl V. Reicin is the International Chair of Mintz’s Life Sciences practice and a trusted advisor to life sciences companies and significant investors in the US, Canada, and countries around the globe. She represents biotechnology, medical device, and health technology companies at all stages of their development as well as venture capitalists, investment banks, and academic medical centers.